Cargando…

Use of Add-on Treatment to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A U.S. Database Study

BACKGROUND: The American Diabetes Association (ADA) recommends metformin to treat individuals diagnosed with type 2 diabetes and recommends that hemoglobin A1c (HbA1c) be maintained below or around 7%. If the HbA1c target is not achieved or maintained by metformin monotherapy at maximal tolerated do...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Shengsheng, Schwab, Phil, Bian, Boyang, Radican, Larry, Tunceli, Kaan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397849/ https://www.ncbi.nlm.nih.gov/pubmed/27003557 http://dx.doi.org/10.18553/jmcp.2016.22.3.272

Ejemplares similares

Factors associated with adherence to oral antihyperglycemic monotherapy in patients with type 2 diabetes
por: Tunceli, Kaan, et al.
Publicado: (2015)

Effect of a New Formulation of Nutraceuticals as an Add-On to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A Randomized Controlled Trial
por: Sartore, Giovanni, et al.
Publicado: (2021)

Trends in add-on medications following metformin monotherapy for type 2 diabetes
por: Swart, Elizabeth CS, et al.
Publicado: (2022)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
por: Villar, Miriam Méndez-del, et al.
Publicado: (2017)

A Survey of Patient Preferences for Oral Antihyperglycemic Therapy in Patients with Type 2 Diabetes Mellitus
por: Hauber, A. Brett, et al.
Publicado: (2015)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Jeon, Ja Young, et al.
Publicado: (2021)

Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus
por: Lin, Yan-Yu, et al.
Publicado: (2022)

Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study
por: Philip, Elizabeth, et al.
Publicado: (2013)

Frequency and predictors of suboptimal glycemic control in an African diabetic population
por: Kibirige, Davis, et al.
Publicado: (2017)

Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study
por: Takahashi, Hiroshi, et al.
Publicado: (2018)

HbA(1c) After a Short Period of Monotherapy With Metformin Identifies Durable Glycemic Control Among Adolescents With Type 2 Diabetes
por: Zeitler, Phil, et al.
Publicado: (2015)

Impact of baseline characteristics on glycemic effects of add‐on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus
por: Fang, Hui, et al.
Publicado: (2020)

Predictors of HbA(1c) treatment response to add-on medication following metformin monotherapy: a population-based cohort study
por: Tan, Wei Ying, et al.
Publicado: (2023)

Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy
por: Inzucchi, S. E., et al.
Publicado: (2015)

Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study
por: Fu, Alex Z, et al.
Publicado: (2010)

Real‐world data on eslicarbazepine acetate as add‐on to antiepileptic monotherapy
por: Holtkamp, M., et al.
Publicado: (2016)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Characteristics of Children with Type 1 Diabetes and Persistent Suboptimal Glycemic Control
por: Kim, Hyuntae, et al.
Publicado: (2012)

Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes
por: Hauber, A Brett, et al.
Publicado: (2013)

Metformin Use in Prediabetes Among U.S. Adults, 2005–2012
por: Tseng, Eva, et al.
Publicado: (2017)

Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study
por: Roberto, Giuseppe, et al.
Publicado: (2022)

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks
por: Kadowaki, Takashi, et al.
Publicado: (2012)

Cardiovascular safety of antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study
por: Katoh, Takao, et al.
Publicado: (2019)

The Change in HbA1c Associated with Initial Adherence and Subsequent Change in Adherence among Diabetes Patients Newly Initiating Metformin Therapy
por: Nichols, Gregory A., et al.
Publicado: (2016)

Secondary Failure of Metformin Monotherapy in Clinical Practice
por: Brown, Jonathan B., et al.
Publicado: (2010)

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
por: White, Judith L, et al.
Publicado: (2014)

Long‐term safety and efficacy of antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study)
por: Yamaguchi, Osamu, et al.
Publicado: (2018)

The Compendium of U.S. jails: creating and conducting research with the first comprehensive contact database of U.S. jails
por: Foudray, Chelsea M. A., et al.
Publicado: (2021)

Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment
por: Tao, Tao, et al.
Publicado: (2018)

Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance
por: Hope, William, et al.
Publicado: (2019)

Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea
por: Shin, Yujin, et al.
Publicado: (2020)

Do inequalities add up? Intersectional inequalities in smoking by sexual orientation and education among U.S. adults
por: Amroussia, Nada, et al.
Publicado: (2019)

Time associations between U.S. birth rates and add-Ons to IVF practice between 2005–2016
por: Gleicher, Norbert, et al.
Publicado: (2021)

Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
por: Cheng, Lan, et al.
Publicado: (2021)

Predictors of metformin monotherapy failure in gestational diabetes mellitus
por: Benido Silva, Vânia, et al.
Publicado: (2022)

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
por: Foody, JoAnne M, et al.
Publicado: (2013)

Impact of Baseline BMI on Glycemic Control and Weight Change with Metformin Monotherapy in Chinese Type 2 Diabetes Patients: Phase IV Open-Label Trial
por: Ji, Linong, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kl6s7ok34s8gcfck61flv855r1